Watson Pharma Hits Record Highs On Actavis Deal
Fri, 04/27/2012 - 07:37 | 
Watson Pharmaceuticals has purchased Actavis for approximately $5.6 billion, paying $1 billion less for the Swiss generic drug manufacturer than initial M&A hearsays had hinted.
Pfizer Inc., the globe’s largest drug manufacturer, and Mylan Inc. stated that they settled patent-infringement lawsuit with Teva Pharmaceutical Industries Ltd. over a device utilized to insert epinephrine during potentially fatal allergies.
Drugmaker Jazz Pharmaceuticals PLC stated that it will get hold of cancer drug manufacturer EUSA Pharma Inc. in a transaction worth around $700 million.
Tags: Roche To Slash Prices Of Two Cancer Medications In India
The Swiss pharmaceutical firm Roche Holding AG has decided to offer sharply discounted editions of two cancer medications in the Indian market.
Patients will expire because of the administration's reforms to the NHS, the editor of a respected medical journal claimed yesterday.
Teva Pharmaceutical Industries, the globe's largest generic drug manufacturer, plans to offer senior notes denominated in euros and Swiss francs outside the US.
Watson Pharmaceuticals soared during noon trading on Wednesday after an anonymously sourced report stated that it is near to buying Swiss counterpart Actavis.
Teva To Trasfer Listing To NYSE By May 2012; Watson Near To $7 billion Actavis Drug Agreement
Teva Pharmaceutical Industries Ltd stated that it is moving its listing of U.S. traded shares to NYSE from the Nasdaq Global Select Market by May 2012.
A federal advisory board on March 20 disapproved the experimental medicine, ridaforolimus, produced by Ariad Pharmaceuticals (ARIA) and joined hands with Merck & Co. (MRK), for utilization in patients with soft-tissue or bone sarcomas.
GlaxoSmithKline and Johnson & Johnson have joined hands with venture capital company Index Ventures to introduce a fund to make investment in life sciences firms, continuing Big Pharma's push to tap into novel drugs while bringing down the billions it has historically expended on internal research and growth.
FDA Gives Nod To No-Comb Head Lice Cure
The FDA has given sanction to the topical ivermectin 0.5% ointment (Sklice) for the cure of head lice in sufferers 6 months and older.
Watson Pharmaceuticals declared that its arm, Watson Laboratories, Inc., has inked a deal with Janssen Pharmaceuticals, Inc. on outstanding patent litigation linked to Watson's generic edition of Janssen's ORTHO TRI-CYCLEN® LO pills.
A novel report said that around 100- 200 million India’s residents might be carrying two deadly types of superbug, ha-MRSA and ca-MRSA – that are said to be resistant to all available antibiotic drugs.
Specialists as well as shareholders of pharmaceutical industry on February 08 called for setting up an autonomous drug regulatory authority (DRA) at federal level to govern, file and fix the costs of medications.
Glenmark Bags DCGI Sanction For Crofelemer Research; NHS Cuts Disturbing Patient Care
Glenmark Pharma has declared that they have bagged the DCGI (India) nod for conduct of the key research of Crofelemer in Acute Watery Diarrhoea sufferers.
Medicis Pharmaceutical Corp. has lifted up its viewpoint for profit this year by a couple of cents per share, even though the drug manufacturer turned down its direction for income owing to renegotiated deals.
Several equity research companies have altered their stock rankings and price objectives on scrips of Watson Pharmaceuticals during the past week.
Four out of five physicians think that patient care suffered during the existing year (2011) owing to NHS cutbacks, as per a novel review.
Watson Pharma Bags USFDA Nod For Antares' Oxybutynin Gel; RBI Notifies New FDI Rules For Pharma Section
Watson Pharmaceuticals, a top integrated global pharma firm, and Antares Pharma, Inc have bagged the USFDA nod for Antares' topical oxybutynin gel 3% medicine for treating overactive bladder (OAB).
ZEVALIN is recently sanctioned by the FDA and commercialized by Spectrum Pharmaceuticals in the United States for treating sufferers with previously untreated follicular non-hodgkin lymphoma.
Auxilium Pharmaceuticals Inc. has named Adrian Adams as president and CEO with immediate effect. Adrian succeeds Armando Anido.
Sun Pharma Buys 3% Stake In Natco Pharma; Ranbaxy Introduces Caduet In United States
Dilip Shanghvi, the originator of Sun Pharmaceutical Industries Ltd, has bought a 3% equity stake in Natco Pharma Ltd. Natco's finance head made this declaration today.
Watson Pharmaceuticals Inc. (WPI) has rolled out a generic edition of Teva Pharma's LoSeasonique oral contraceptive pill under a settlement with the drug manufacturer.
A multi million pound package of measures were sketched by the PM David Cameron to back up the UK’s life sciences business and endorse faster access to novel medications
for patients.
Ranbaxy Laboratories has introduced an official generic edition of Caduet in the United States, as part of a pact with Pfizer Inc.
